Abstract:Abstract Background: Small cell lung cancer (SCLC) is a highly aggressive disease for which standard treatment remains virtually unchanged since the 1980s. SCLC has a relatively immunosuppressed phenotype with low levels of infiltrating T-cells and evidence of reduced antigen presentation. Only a minority of SCLC patients responds to programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors as monotherapy. Therefore, though the clinical data is promising, there is a strong need to develop strategies to enhance the efficacy of immunotherapy in SCLC. Our group previously discovered that the DNA damage repair (DDR) protein, checkpoint kinase 1 (CHK1), is overexpressed in SCLC and that CHK1 inhibitors have activity in preclinical models of SCLC. Based on data from others and our group, we hypothesize that tumor associated neoantigen (TAA) expression is suppressed in SCLC by several mechanisms, including DDR machinery, and that targeting CHK1 may enhance antitumor immunity and response to immune checkpoint targeting. Results: In SCLC models, inhibition of CHK1 by genetic knockdown and small molecule inhibition (LY2606368) induces DNA damage as demonstrated by increased γ-H2AX levels. We also observed increased protein levels of immune checkpoint ligand, PD-L1, following pharmacologic inhibition with LY2606368. We next tested whether co-targeting CHK1+PD-L1 enhances the anti-tumor effect in an immune-competent SCLC model. B6129F1 mice were injected in the flank with TKO.mTmG cells harboring conditional deletion of Trp53, Rb1 and p130. When the tumor volume reached 120mm3, mice were treated with either IgG (control), LY2606368 (10mg/kg, 2/7), anti-PD-L1 (300ug, 1/7) or combination of LY2606368 and anti-PD-L1 antibody. Single agent treatment with anti-PD-L1 antibody did not cause tumor regression in these models with T/C ratio=0.93 (p<0.001) at Day 21. Treatment of single agent LY2606368 at a sub-therapeutic dose significantly delayed tumor growth in these models with T/C=0.31 (p<0.001) at Day 21. However, 3 out of 5 mice treated with anti-PD-L1+LY2606368 had a complete tumor regression within 15 days of treatment with T/C=0.05 (p<0.001) at Day 21. Tumors were collected at the end of 21 days for RPPA analysis, RNA sequencing and flow cytometry to characterize tumor-infiltrating immune cells post treatment with the single agents versus the combination. Discussion: SCLC has an immunosuppressed phenotype (despite a high mutational burden); however, only a minority of tumors expresses PD-L1, suggesting that immunosuppressive mechanisms other than the PD-1/PD-L1 pathway are likely to contribute. This study shows that targeting CHK1 (by genetic knockdown and pharmacological inhibition) leads to increased DNA damage and increased expression of immune checkpoint ligand, PD-L1. Combining CHK1 inhibition and PD-L1 targeting significantly enhanced the effect of PD-L1 antibody leading to tumor regression in an immune competent SCLC model. Biomarker analyses from these models are ongoing to confirm the expression of immune markers. PD-L1 inhibitors as monotherapy have led to objective responses in only a minority of SCLC patients. The CHK1 inhibitor LY2606368 is currently in clinical trial for SCLC patients. The complementary modes of action of the two promising modalities, immune checkpoint targeting and CHK1 inhibition, suggest intriguing possibilities for therapeutic synergy with combination treatment and warrants further clinical investigation. Citation Format: Triparna Sen, Limo Chen, Bertha Leticia Rodriguez, Yongbin Yang, You Hong Fan, Catherine Allison Stewart, Bonnie Glisson, Helen Piwnica-Worms, Julien Sage, John V. Heymach, Don L. Gibbons, Lauren A. Byers. Combining immune checkpoint inhibition and DNA damage repair (DDR) targeted therapy in small cell lung cancer (SCLC). [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2016 Oct 20-23; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2017;5(3 Suppl):Abstract nr B72.

Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.

BRCA1 orchestrates the response to BI-2536 and its combination with alisertib in MYC-driven small cell lung cancer

Polo-like Kinase 1 Inhibitor BI6727 Sensitizes 9L Gliosarcoma Cells to Ionizing Irradiation

Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.

Polo-like Kinase 1 Inhibitors in Human Cancer Therapy: Development and Therapeutic Potential

A Cereblon Modulator CC-885 Induces CRBN- and P97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer.

Targeted Inhibition of Polo‐like Kinase 1 by a Novel Small‐molecule Inhibitor Induces Mitotic Catastrophe and Apoptosis in Human Bladder Cancer Cells

Plk1 As A Potential Drug Target in Cancer Therapy

A PLK1 Kinase Inhibitor Enhances the Chemosensitivity of Cisplatin by Inducing Pyroptosis in Oesophageal Squamous Cell Carcinoma.

A Series of Beta-Carboline Derivatives Inhibit the Kinase Activity of Plks

Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells

P3.02c-004 SBI0206965, a Novel Inhibitor of Ulk1, Suppresses Non-Small Cell Lung Cancer Cell Growth Via Modulating Both Autophagy and Apoptosis Pathways: Topic: Targeted Therapy

Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001

Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment

Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer.

Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide–Hoechst Conjugate Suppresses Tumor Growth in Vivo

In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53

Abstract B72: Combining Immune Checkpoint Inhibition and DNA Damage Repair (DDR) Targeted Therapy in Small Cell Lung Cancer (SCLC)

SCH 727965, a Novel Cyclin-Dependent Kinase Inhibitor, Has Potent Anti-Tumor Acitivity in a Wide-Spectrum of Human Tumor Xenograft Models

Identification of A Novel Polo-Like Kinase 1 Inhibitor That Specifically Blocks the Functions of Polo-Box Domain

Cytotoxic Mechanism of PLK1 Inhibitor GSK461364 Against Osteosarcoma: Mitotic Arrest, Apoptosis, Cellular Senescence, and Synergistic Effect with Paclitaxel.